On 8 October 2026 the Supreme Court directed the Union of India to constitute a committee to recommend statutory regulation of pharmaceutical marketing practices. The order was passed in Federation of Medical and Sales Representatives Associations of India & Ors. v. Union of India & Ors., W.P.(C) No. 323/2021, as reported by LiveLaw. This note records what was directed and what it means for compliance teams. The petition is pending, so it reports the direction only.

What the Court directed

A bench of Justices Vikram Nath and Sandeep Mehta, as reported:

• The Union must constitute a committee to recommend statutory regulations on unethical pharmaceutical marketing. The Solicitor General indicated it would have three members.
• The committee is to examine whether the existing statutory and regulatory framework is adequate, and how effective monitoring, oversight and enforcement are.
• It must consider the material already before the Court, give petitioners, intervenors and other stakeholders an opportunity to comment, and may take help from experts or institutions.
• It must finish within two months of its first meeting and submit recommendations to the Union.
• The Centre is to take a reasoned decision at the earliest, keeping Article 21 and the public interest in view.
• The Union must file a compliance affidavit on the constitution of the committee, its first meeting, the consultation, the recommendations and the Government’s decision. The matter is to come up on 29 January 2027.

The framework in place today

The Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 continues to govern marketing in the meantime, as the Court noted. The report also says existing rules allow disciplinary action against doctors who accept gifts, travel, hospitality or grants from pharma companies. The Court observed that the framework has “not proved entirely effective” and that effectiveness depends on implementation and enforcement, not only on prescribed norms. At an earlier hearing, it had asked whether the UCPMP, without government control, risked being almost voluntary.

Petitioners’ counsel argued that penalties fall on doctors but there is no matching statutory penalty for companies. That is a submission, not a finding.

What the Court left to the executive

The Court stressed separation of powers: choosing the statutory model and oversight mechanism is a policy matter for the legislature and executive, and it would not substitute its own view. Its role at this stage, it said, is to facilitate a meaningful consultative process.

Why compliance teams should note it

• No new obligation yet. The order creates a process, not a rule. Existing obligations, including the UCPMP 2024 and any applicable professional or tax rules, continue as they are.
• Direction of travel. A committee examining “statutory” regulation signals that enforceability, and not only voluntary codes, is under review. What it will recommend is not known.
• Timeline. Two months from the committee’s first meeting, then a Government decision, then the compliance affidavit listed for 29 January 2027.
• Records. Companies, distributors and medical-representative bodies may wish to review how marketing spend, hospitality and sponsorships are documented under their current policies. That is a general observation, not advice for any entity.

What the order does not decide

• It does not hold any company or doctor liable.
• It does not enact or amend any law, or change the UCPMP.
• It does not say what the committee must recommend.

FAQ

1. Has the Supreme Court banned freebies to doctors? No. The order, as reported, directs a committee to recommend regulation. Current rules continue to apply.

2. Does the UCPMP 2024 still apply? The Court noted that it continues to govern marketing in the interim.

3. When will the committee report? Within two months of its first meeting, as reported. The Union’s compliance affidavit is listed on 29 January 2027.

4. Does this change anything for companies today? The order sets a process only. Its effect will depend on what the committee recommends and what the Government decides.

Disclaimer

This is general legal awareness, not legal advice. Legal outcomes depend on facts, documents, law, forum, evidence, limitation and judicial discretion — no outcome is guaranteed. Consult a qualified advocate on your own facts.

Adv. Prakhar Gupta — enrolled with the Bar Council of Rajasthan, Enrolment No. R/2196/2020. This page shares legal awareness/education only; it is not advertisement or solicitation of work.

Parts of this content (images/voice/summary) were created or edited using AI tools.

Source: LiveLaw report of the 8 October 2026 order; the order text was not read for this draft — see Sources file.